Paul Actor

1.3k total citations
72 papers, 988 citations indexed

About

Paul Actor is a scholar working on Pharmacology, Molecular Biology and Infectious Diseases. According to data from OpenAlex, Paul Actor has authored 72 papers receiving a total of 988 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Pharmacology, 24 papers in Molecular Biology and 16 papers in Infectious Diseases. Recurrent topics in Paul Actor's work include Antibiotics Pharmacokinetics and Efficacy (26 papers), Antibiotic Resistance in Bacteria (15 papers) and Phenothiazines and Benzothiazines Synthesis and Activities (11 papers). Paul Actor is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (26 papers), Antibiotic Resistance in Bacteria (15 papers) and Phenothiazines and Benzothiazines Synthesis and Activities (11 papers). Paul Actor collaborates with scholars based in United States, United Kingdom and Canada. Paul Actor's co-authors include Jerry A. Weisbach, Donald Pitkin, George L. Dunn, John R. E. Hoover, Ian Zajac, Sarah F. Grappel, Robert M. DeMarinis, William D. Kingsbury, John F. Pauls and David A. Berges and has published in prestigious journals such as Nature, Science and The Journal of Immunology.

In The Last Decade

Paul Actor

69 papers receiving 795 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paul Actor United States 17 320 277 231 191 177 72 988
Sachiko Gotô Japan 20 346 1.1× 411 1.5× 162 0.7× 141 0.7× 247 1.4× 92 1.1k
Barbara A. Pelak United States 14 302 0.9× 329 1.2× 205 0.9× 175 0.9× 241 1.4× 28 939
L. Tybring Denmark 12 392 1.2× 264 1.0× 174 0.8× 142 0.7× 238 1.3× 24 917
H. H. Gadebusch United States 18 219 0.7× 254 0.9× 196 0.8× 138 0.7× 159 0.9× 63 952
Martin Forbes United States 18 147 0.5× 392 1.4× 193 0.8× 274 1.4× 121 0.7× 42 1.2k
Roy Cleeland United States 21 307 1.0× 420 1.5× 159 0.7× 112 0.6× 249 1.4× 66 1.2k
J. Allan Waitz United States 21 632 2.0× 449 1.6× 209 0.9× 174 0.9× 428 2.4× 56 1.4k
M Berti Italy 17 520 1.6× 493 1.8× 329 1.4× 243 1.3× 136 0.8× 43 1.1k
A. R. English United States 16 520 1.6× 271 1.0× 242 1.0× 209 1.1× 395 2.2× 45 1.3k
B. A. Newton United Kingdom 17 177 0.6× 447 1.6× 81 0.4× 121 0.6× 246 1.4× 30 1.2k

Countries citing papers authored by Paul Actor

Since Specialization
Citations

This map shows the geographic impact of Paul Actor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Actor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Actor more than expected).

Fields of papers citing papers by Paul Actor

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Actor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Actor. The network helps show where Paul Actor may publish in the future.

Co-authorship network of co-authors of Paul Actor

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Actor. A scholar is included among the top collaborators of Paul Actor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Actor. Paul Actor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Moore, Thomas, et al.. (1995). Susceptibilities of nontuberculosis mycobacterial species to amoxicillin-clavulanic acid alone and in combination with antimycobacterial agents. Antimicrobial Agents and Chemotherapy. 39(7). 1454–1457. 12 indexed citations
2.
Bhatnagar, Pradip K., et al.. (1994). Efficacy of the hematoregulatory peptide SK&F 107647 in experimental systematic Candida albicans infections in normal and immunosuppressed mice. Immunopharmacology. 27(3). 199–206. 14 indexed citations
3.
Actor, Paul. (1988). Antibiotic inhibition of bacterial cell surface assembly and function. 191 indexed citations
4.
Bartus, H F, et al.. (1985). Indications that the erythrocyte receptor involved in enterotoxigenic Escherichia coli attachment is a sialoglycoconjugate. Journal of Clinical Microbiology. 21(6). 951–954. 18 indexed citations
5.
Actor, Paul, et al.. (1985). Aridicins, novel glycopeptide antibiotics. I. Taxonomy, production and biological activity.. The Journal of Antibiotics. 38(5). 555–560. 23 indexed citations
6.
Friedman, Herman & Paul Actor. (1984). Infections in the compromised host. Clinical Immunology Newsletter. 5(4). 60–62. 3 indexed citations
7.
Kingsbury, William D., et al.. (1984). Anti-Candida activity of polyoxin: example of peptide transport in yeasts. Antimicrobial Agents and Chemotherapy. 25(3). 373–374. 36 indexed citations
8.
Grappel, Sarah F., et al.. (1984). Antimicrobial activity of SK&F 88070, an expanded-spectrum cephalosporin with high and prolonged levels in blood. Antimicrobial Agents and Chemotherapy. 25(6). 694–700. 1 indexed citations
9.
Rake, James, David Newman, & Paul Actor. (1984). Affinity of cefonicid, a long-acting cephalosporin, for the penicillin-binding proteins of Escherichia coli K-12.. The Journal of Antibiotics. 37(5). 572–576. 1 indexed citations
10.
Grappel, Sarah F., et al.. (1983). Prophylactic activity of cephalosporins in a mouse model of surgical wound infection.. The Journal of Antibiotics. 36(2). 161–166. 7 indexed citations
11.
Zajac, Ian, et al.. (1982). Isopycnic separation of Escherichia coli cultures possessing colonization factor antigen I. Journal of Clinical Microbiology. 15(6). 1074–1076. 3 indexed citations
12.
Sedlock, David M., H F Bartus, Ian Zajac, & Paul Actor. (1981). Analysis of parameters affecting the hemagglutination activity of Escherichia coli possessing colonization factor antigens: improved medium for observing erythrocyte agglutination. Journal of Clinical Microbiology. 13(2). 301–308. 9 indexed citations
13.
Mehta, R. J., et al.. (1981). Cefonicid: A stable .BETA.-lactamase inhibitor.. The Journal of Antibiotics. 34(2). 202–205. 10 indexed citations
14.
Grappel, Sarah F., et al.. (1980). Correlation of agar-disc-diffusion tests with minimum inhibitory concentrations of cefonicid (SK&F 75073) and cephalothin.. The Journal of Antibiotics. 33(1). 85–87. 8 indexed citations
15.
Pitkin, Donald, Paul Actor, & Jerry A. Weisbach. (1980). Serum Protein Binding Alterations of Selected Cephalosporin Antibiotics by Fatty Acids and Their Derivatives. Journal of Pharmaceutical Sciences. 69(3). 354–356. 8 indexed citations
16.
Actor, Paul, et al.. (1979). Crystallization and antifungal activity of primycin.. The Journal of Antibiotics. 32(11). 1207–1209. 12 indexed citations
17.
Pitkin, Donald, et al.. (1977). Comparative Stability of Cephalothin and Cefazolin in Buffer or Human Serum. Antimicrobial Agents and Chemotherapy. 12(2). 284–285. 4 indexed citations
18.
Pitkin, Donald, et al.. (1975). Automated Spectrophotometric Assay of Cefazolin. Journal of Pharmaceutical Sciences. 64(7). 1232–1234. 10 indexed citations
19.
Winchurch, Richard A. & Paul Actor. (1972). The Effects of an Immunoenhancing Bacterial Product on the Adenyl Cyclase Activity of Mouse Spleen Cells. The Journal of Immunology. 108(5). 1305–1311. 6 indexed citations
20.
Actor, Paul, et al.. (1962). Potentiation of Amphotericin B Activity Against Trypanosoma congolense in Mice. Experimental Biology and Medicine. 110(3). 409–412. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sachiko Gotô Breakdown of academic impact, for papers by Barbara A. Pelak Breakdown of academic impact, for papers by L. Tybring Breakdown of academic impact, for papers by H. H. Gadebusch Breakdown of academic impact, for papers by Martin Forbes Breakdown of academic impact, for papers by Roy Cleeland Breakdown of academic impact, for papers by J. Allan Waitz Breakdown of academic impact, for papers by M Berti Breakdown of academic impact, for papers by A. R. English Breakdown of academic impact, for papers by B. A. Newton
Rankless by CCL
2026